Androgens in childhood acquired aplastic anaemia in Chandigarh, India

Trop Doct. 2004 Jul;34(3):149-52. doi: 10.1177/004947550403400307.


This study assessed the efficacy of stanozolol in acquired aplastic anaemia (AA) in children, who were unable to opt for alternative therapies due to financial constraints. It uses a retrospective case-record analysis. Medical records of children with AA who received stanozolol were analysed. Their clinical and haematological profile was studied and the outcome assessed. Forty-nine children with acquired AA received stanozolol (1 mg/kg/day) in the period between January 1991 and December 2000. The median age at diagnosis was 9 years (range: 1.5-13). Thirteen (26.5%) defaulted therapy after periods of 1-4 weeks and 11 (22.4%) died within 2 months of starting treatment. Ten (20.4%) responded, whilst 15 (30.6%) did not. None of the patients with very severe AA responded, two (28.6%) with severe AA responded and eight (38%) with non-severe AA had a response. All responses were partial except one. Median time taken to respond was 11 weeks (range: 1-20). Responders were treated for a median duration of 25 weeks (range: 13-155), and they were followed-up for a median duration of 25 months (range: 3-144). Eight (80%) responders were off drugs for a median duration of 18 months (range: 6-110). Stanazolol is ineffective for severe and very severe AA. As it induced remission in 38% of our patients with non-severe AA, it can be tried in this group if other methods of treatment are unaffordable or have failed. A short history of presentation (< 3 months) and > or = 70% lymphoid cells in marrow correlated with poor prognosis.

MeSH terms

  • Adolescent
  • Androgens / therapeutic use*
  • Anemia, Aplastic / drug therapy*
  • Anemia, Aplastic / epidemiology*
  • Anemia, Aplastic / etiology
  • Anemia, Aplastic / pathology
  • Child
  • Child, Preschool
  • Female
  • Humans
  • India / epidemiology
  • Infant
  • Male
  • Medical Records
  • Retrospective Studies
  • Severity of Illness Index
  • Stanozolol / therapeutic use*
  • Treatment Outcome


  • Androgens
  • Stanozolol